Clinical Trial Detail

NCT ID NCT02406742
Title A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene Corporation
Indications

CLL/SLL

Therapies

Obinutuzumab

Rituximab

Ibrutinib

CC-122

Age Groups: adult

No variant requirements are available.